On 27 July 2020, orphan designation EU/3/20/2299 was granted by the European Commission to Ascendis Pharma Growth Disorders A/S, Denmark, for c-type natriuretic peptide conjugated to multi-arm polyethylene glycol carrier through a cleavable linker for the treatment of achondroplasia.
C-type natriuretic peptide conjugated to multi-arm polyethylene glycol carrier through a cleavable linker
Treatment of achondroplasia
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: